Intrathecal effects of daclizumab treatment of multiple sclerosis
نویسنده
چکیده
Raphael Schneider, MD Nathalie Arbour, PhD The topic of this Journal Club is a study by Bielekova et al.,1 who assessed whether daclizumab monotherapy reduces contrast-enhancing lesions (CEL) in patients with relapsing-remitting multiple sclerosis (RRMS). Furthermore, they evaluated the effects of daclizumab on clinical outcome measures and on NK cell populations in the CSF and blood of treated patients.
منابع مشابه
Journal club: Intrathecal effects of daclizumab treatment of multiple sclerosis.
Raphael Schneider, MD Nathalie Arbour, PhD The topic of this Journal Club is a study by Bielekova et al.,1 who assessed whether daclizumab monotherapy reduces contrast-enhancing lesions (CEL) in patients with relapsing-remitting multiple sclerosis (RRMS). Furthermore, they evaluated the effects of daclizumab on clinical outcome measures and on NK cell populations in the CSF and blood of treated...
متن کاملIntrathecal effects of daclizumab treatment of multiple sclerosis.
OBJECTIVES We previously reported that daclizumab, a humanized monoclonal antibody against CD25, reduced contrast-enhancing lesions (CEL) in patients with multiple sclerosis (MS) who were suboptimal responders to interferon-β and that this response correlated with expansion of CD56(bright) NK cells. These data have been reproduced in a placebo-controlled multicenter trial (CHOICE study). The cu...
متن کاملDaclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis
OBJECTIVE Novel treatments such as natalizumab and fingolimod achieve their therapeutic efficacy in multiple sclerosis (MS) by blocking access of subsets of immune cells into the central nervous system, thus creating nonphysiological intrathecal immunity. In contrast, daclizumab, a humanized monoclonal antibody against the alpha chain of the IL-2 receptor, has a unique mechanism of action with ...
متن کاملPharmacodynamic effects of daclizumab in the intrathecal compartment
OBJECTIVE It was previously demonstrated that daclizumab therapy normalizes cellular cerebrospinal fluid (CSF) abnormalities typical of multiple sclerosis (MS) in the majority of treated patients. However, CSF cells represent only the mobile portion of intrathecal immune responses. Therefore, we asked whether daclizumab also reverses compartmentalized inflammation and if not, whether residual i...
متن کاملDaclizumab use in patients with pediatric multiple sclerosis.
BACKGROUND Daclizumab, a humanized monoclonal antibody specific for the interleukin 2 receptor α chain, reduces clinical and magnetic resonance imaging disease activity in patients with adult-onset multiple sclerosis (MS) as monotherapy or add-on therapy with interferon. OBJECTIVE To report the use of daclizumab in pediatric-onset MS. DESIGN Case series. SETTING Two comprehensive pediatri...
متن کامل